These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1132185)

  • 1. Impaired osteoclastic function and linear bone erosion rate in secondary hyperparathyroidism associated with chronic renal failure.
    Jaworski ZF; Lok E; Wellington JL
    Clin Orthop Relat Res; 1975; (107):298-310. PubMed ID: 1132185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of cortical remodeling sites in longitudinal rib sections of beagles with renal failure and parathyroid hyperplasia.
    Norrdin RW; Shih MS
    Metab Bone Dis Relat Res; 1983; 4(6):353-9. PubMed ID: 6664307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid sonography in secondary hyperparathyroidism: correlation with clinical findings.
    Tomić Brzac H; Pavlović D; Halbauer M; Pasini J
    Nephrol Dial Transplant; 1989; 4(1):45-50. PubMed ID: 2494598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
    Zucchi C
    Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
    [No Abstract]   [Full Text] [Related]  

  • 5. Skeletal resistance to the calcaemic action of parathyroid hormone in uraemia: a mechanism for the hypocalcaemia and secondary hyperparathyroidism of chronic renal failure.
    Massry SG
    Clin Endocrinol (Oxf); 1976; 5 Suppl():317S-325S. PubMed ID: 1052781
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats.
    Oste L; Behets GJ; Dams G; Bervoets AR; Marynissen RL; Geryl H; Van Hoof VO; De Broe ME; D'Haese PC
    Ren Fail; 2007; 29(1):1-12. PubMed ID: 17365904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rate of osteoclastic bone erosion in Haversian remodeling sites of adult dog's rib.
    Jaworski ZF; Lok E
    Calcif Tissue Res; 1972; 10(2):103-12. PubMed ID: 5083910
    [No Abstract]   [Full Text] [Related]  

  • 8. Sevelamer hydrochloride suppresses proliferation of parathyroid cells during the early phase of chronic renal failure in rats.
    Xiao X; Liu Y; Zhong X; Liu Y; Zhou D; Xiong X; Ran J
    Nephrology (Carlton); 2019 Jan; 24(1):127-133. PubMed ID: 29278442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperparathyroidism and experimental chronic renal failure.
    Boquist L; Bergdahl L; Andersson L
    Urol Res; 1973 May; 1(2):43-9. PubMed ID: 4775661
    [No Abstract]   [Full Text] [Related]  

  • 11. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines].
    Brancaccio D; Galmozzi C; Pizzocaro G
    Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
    O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
    Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
    [No Abstract]   [Full Text] [Related]  

  • 13. Parathyroid morphology in suppressible and nonsuppressible renal hyperparathyroidism.
    Black WC; Slatopolsky E; Elkan I; Hoffsten P
    Lab Invest; 1970 Nov; 23(5):497-509. PubMed ID: 5483883
    [No Abstract]   [Full Text] [Related]  

  • 14. [A case of secondary hyperparathyroidism; discussion of tertiary hyperparathyroidism].
    Huguenin A; Richier JL; Chevrel ML; Ferrand B; Guérin D; Murie N
    Ann Endocrinol (Paris); 1971; 32(3):409-29. PubMed ID: 5114906
    [No Abstract]   [Full Text] [Related]  

  • 15. Insufficiency of PTH action on bone in uremia.
    Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
    Kidney Int Suppl; 2006 Jul; (102):S34-6. PubMed ID: 16810309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a diphosphonate on uremic hyperparathyroidism.
    Kaye M
    Nephron; 1973; 10(2):188-94. PubMed ID: 4710979
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythrocyte survival in chronic renal failure. Role of secondary hyperparathyroidism.
    Akmal M; Telfer N; Ansari AN; Massry SG
    J Clin Invest; 1985 Oct; 76(4):1695-8. PubMed ID: 4056047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mechanism for skeletal resistance in uremia.
    Slatopolsky E; Finch J; Clay P; Martin D; Sicard G; Singer G; Gao P; Cantor T; Dusso A
    Kidney Int; 2000 Aug; 58(2):753-61. PubMed ID: 10916099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
    Geng Z; Monier-Faugere MC; Bauss F; Malluche HH
    Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism in chronic renal failure.
    Malmaeus J
    Scand J Urol Nephrol Suppl; 1983; 70():1-63. PubMed ID: 6351238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.